Literature DB >> 28622326

Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.

V E Konidaris1, K T Tsaousis1, Z Al-Hubeshy1, K Pieri1, J Deane1, T Empeslidis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28622326      PMCID： PMC5684456          DOI： 10.1038/eye.2017.122

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

1.  Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.

Authors:  Chirag P Shah; Jeffrey S Heier
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-09-01       Impact factor: 1.300

2.  Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.

Authors:  Edward H Wood; Peter A Karth; Darius M Moshfeghi; Theodore Leng
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-10       Impact factor: 1.300

3.  Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.

Authors:  Laurence S Lim; Wei Yan Ng; Ranjana Mathur; Doric Wong; Edmund Ym Wong; Ian Yeo; Chui Ming Gemmy Cheung; Shu Yen Lee; Tien Yin Wong; Thanos D Papakostas; Leo A Kim
Journal:  Clin Ophthalmol       Date:  2015-09-16
  3 in total
  5 in total

1.  Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Authors:  Michael S Ip; Neal L Oden; Ingrid U Scott; Paul C VanVeldhuisen; Barbara A Blodi; Thomas Ghuman; Carl W Baker
Journal:  JAMA Ophthalmol       Date:  2019-03-01       Impact factor: 7.389

2.  Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings.

Authors:  Anastasios E Sepetis; Holly Clarke; Bhaskar Gupta
Journal:  Int J Retina Vitreous       Date:  2022-04-01

3.  Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.

Authors:  Rafael Campos Polo; Consuelo Rubio Sánchez; Diego Manuel García Guisado; María José Díaz Luque
Journal:  Clin Ophthalmol       Date:  2018-01-08

4.  Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion.

Authors:  Vasileios E Konidaris; Konstantinos T Tsaousis; Rossella Anzidei; Guillermo de la Mata; Alexander J Brent
Journal:  Ophthalmol Ther       Date:  2018-10-04

5.  Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.

Authors:  Yilin Liu; Jiahan Cheng; Yunxia Gao; Ling Qin; Xiaoxue Min; Ming Zhang
Journal:  Ann Transl Med       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.